Tecentriq Now Approved as First Treatment for Advanced Bladder Cancer in Some Patients
FDA NewsNewsworthy
On April 17, 2017, the FDA approved the PD-L1 inhibitor Tecentriq (atezolizumab; from Genentech) for use as first-line treatment for patients with locally advanced or metastatic urothelial carcinoma who cannot use cisplatin chemotherapy.
New Cancer Drugs
FDA NewsNewsworthy
This section provides a brief overview of new medications approved by the FDA between the end of December 2016 and mid-March 2017.
Kisqali a New First-Line Treatment for Patients with Advanced Breast Cancer
FDA NewsNewsworthy
In March 2017, the FDA approved Kisqali (ribociclib), in combination with an aromatase inhibitor, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Keytruda Now Available for Patients with Relapsed Classical Hodgkin Lymphoma
FDA NewsNewsworthy
In March 2017, the FDA approved Keytruda (pembrolizumab), anti-PD-1 immunotherapy, for the treatment of patients with classical Hodgkin lymphoma who are not responding to other therapy or whose disease (relapsed) returned after 3 or more therapies. Keytruda was previously approved for several cancers.
Revlimid Approved for Maintenance Therapy in Patients with Multiple Myeloma After Transplant
FDA NewsNewsworthy
In February 2017, the FDA approved the oral drug Revlimid (lenalidomide) for maintenance (continuing) therapy for patients with multiple myeloma who had autologous hematopoietic stem-cell transplant. Revlimid was previously approved for multiple myeloma and for other types of cancer.
Page 3 of 4
Results 21 - 30 of 38

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.